Citius Pharmaceuticals, Inc.
CTXR · XNASCIK 1506251fmd_0EK6JCBWD1RNF4W6XK4CG04TJW制造业 · 医药制剂模板: 标准
覆盖范围: 2009年10月01日 至 2026年6月30日，共 64 个期间
| 项目 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| 营业总收入 | – | 0 | 0 | 0 | 0 | 0 | 0 | – | – | – |
| 净利息收入 | 0 | – | – | – | – | – | – | – | – | – |
| 营业成本 | 0 | 0 | 0 | – | – | – | – | – | – | – |
| 毛利润 | – | 0 | 0 | – | – | – | – | – | – | – |
| 研发费用 | 3 | 3 | 7 | 0 | 9 | 12 | 18 | 15 | 12 | 9 |
| 营业费用合计 | 7 | 10 | 14 | 16 | 18 | 24 | 33 | 37 | 42 | 39 |
| 营业利润 | (7) | (10) | (14) | (16) | (18) | (24) | (33) | (37) | (42) | (39) |
| 利息费用 | 0 | 1 | 0 | 0 | 0 | 0 | – | – | – | 0 |
| 利息及投资收益 | 0 | – | – | 0 | 0 | 0 | 0 | 1 | 1 | 0 |
| 其他营业外收入（支出） | (1) | (0) | 1 | 0 | 0 | 0 | 0 | 5 | 3 | (0) |
| 税前利润 | (8) | 10 | 13 | (16) | (18) | (23) | (33) | (32) | (39) | (39) |
| 所得税费用 | – | – | – | – | 0 | 0 | 1 | 1 | 1 | 1 |
| 持续经营净利润 | – | – | – | – | (18) | (23) | (34) | (33) | (39) | (40) |
| 净利润 | (8) | (10) | (13) | (16) | (18) | (23) | (34) | (33) | (39) | (40) |
| 归属于普通股股东的净利润 | – | – | – | – | (18) | (25) | (34) | (34) | (40) | (37) |